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Purpose: The perioperative management of patients who are receiving antithrombotic (antiplatelet 
or anticoagulant) therapy and require urologic surgery is challenging due to the inherent risk for 
surgical bleeding and the need to minimize thromboembolic risk. The aim of this review is to assess 
the quality and consistency of clinical practice guidelines (CPGs) and clinical practice 
recommendations (CPRs) on this topic, and to summarize the evidence and associated strength of 
recommendations relating to perioperative antithrombotic management.  
Methods: A pragmatic search of electronic databases and guidelines websites was performed to 
identify relevant CPGs/CPRs. The AGREE II (Appraisal of Guidelines for REsearch and Evaluation) 
instrument was used to assess the methodological quality and integrity of the CPGs. 
Results: The CPGs provided by the European Association of Urology (EAU), the American College of 
Chest Physicians (ACCP) and the European Society of Cardiology/European Society of Anaesthesiology 
(ESC/ESA), and the CPRs provided by the International Consultation on Urological Disease 
(ICUD)/American Urologic Association (AUA) were retrieved and reviewed. The 3 CPGs were critically 
assessed using the AGREE II instrument.   Inconsistent recommendations were provided based on the 
indication for antithrombotic medication, the antiplatelet/anticoagulant agent and the type of 
urological procedure. Based on the AGREE II tool for CPG assessment, the EAU CPGs scored higher 
(83.3 points) compared to the ESC/ESA (75 points) and ACCP CPG (66.7 points).  
Conclusion: The perioperative management of antithrombotic therapy in urological patients is 
potentially challenging but inconsistent CPG of varying quality may create uncertainty as to best 





Acute or elective management of patients on antithrombotic (antiplatelet or anticoagulant) 
therapy  presents a challenge for surgeons because of the intrinsic risk for intra- and post-operative 
bleeding associated with most urologic surgery and the need to minimize thromboembolic risk. With 
an aging population, an increasing number of patients are receiving anticoagulant therapy for stroke 
prevention in atrial fibrillation (AF) or the management of venous thromboembolism (VTE) and 
antiplatelet therapy for coronary or peripheral vascular disease. Such patients, typically, have multiple 
comorbidities that increase thromboembolic risk. The rationale for withholding antithrombotic 
therapy during the perioperative period is to minimize blood loss during and after surgery; however, 
this approach needs to be balanced against the risk of perioperative thromboembolism that may arise 
after stopping treatment, especially in high-risk patients.  
Among antiplatelet drugs, aspirin irreversibly binds to cycloxygenase (COX)-1, effectively inhibiting 
thromboxane A2 production and platelet aggregation, whereas P2Y12 receptor inhibitors, comprising 
clopidogrel, prasugrel and ticagrelor, reduce platelet aggregation by inhibiting the activation of the 
glycoprotein IIb/IIIa receptor complex.[1–5] Dipyridamole, which is typically combined therapeutically 
with aspirin, inhibits cyclic adenosine monophosphate (cAMP) phosphodiesterase, increases platelet 
cAMP levels and reduces thromboxane A2 activity and platelet aggregation.[6][7] Less commonly used 
agents are abciximab, eptifibatide and tirofiban, which act on platelet glycoprotein IIb/IIIa receptors 
to inhibit platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and 
other adhesive molecules.[8–10] 
Anticoagulant medications, on the other hand, suppress thrombus formation and propagation by 
targeting different clotting factors involved in the coagulation cascade that culminates with the 
production of fibrin. As venous thrombi contain high levels of fibrin, anticoagulants mainly reduce the 
incidence of venous thromboembolic events, but anticoagulants are also effective to prevent 
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intracardiac thrombus formation in patients with AF, thereby reducing the risk for cardioembolic 
stroke. 
Among anticoagulant drugs, warfarin decreases blood clotting by blocking reactivation of 
vitamin K1; without sufficiently active vitamin K1, clotting factors II, VII, IX, and X have decreased 
clotting ability.[11] Unfractionated heparin binds reversibly to antithrombin III and greatly accelerates 
the rate at which it inactivates thrombin (factor IIa) and factor Xa. Low-molecular-weight heparins 
(LMWHs) bind and activate antithrombin, with a stronger affinity to factor Xa than unfractionated 
heparin and affect only the intrinsic coagulation cascade. Fondaparinux is a selective factor Xa 
inhibitor that prevents the conversion of prothrombin to thrombin. [12] Direct oral anticoagulants 
(DOACs) include dabigatran and factor Xa inhibitors. Dabigatran etexilate is an oral prodrug that 
disrupts the coagulation cascade and inhibits the formation of clots by offering reversible and direct 
inhibition of direct thrombin.[13] Rivaroxaban, apixaban and edoxaban are factor Xa inhibitors. All 
DOACs inhibit the formation of circulating and clot-bound thrombin and have no effects on platelet 
function.[14–18] With respect to reversibility of action, dabigatran can be reversed selectively with 
idarucizumab, a humanized monoclonal antibody fragment, while further reversal agents for DOACs 
are on the horizon.Table 1 summarizes the characteristics and pharmacological properties of the 
currently available main antithrombotic agents. For perioperative, it is important to note that their 
elimination half-lives are 10-14 hours (longer for patients taking dabigatran and have impaired renal 
function) and have a rapid (1-3 hour) peak anticoagulant effect after oral intake. 
In the urological setting, surgeons will frequently need to decide on the perioperative 
management of patients on anticoagulants or antiplatelets undergoing open or endoscopic, acute or 
elective urological procedures. The number of patients taking antithrombotic agents has increased in 
the past decade, especially as DOAC have become widely used in patients with AF and VTE. Thus, it is 
critical for the surgeon to be aware of the characteristics of antithrombotic agent and their mechanism 
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of action to facilitate decision-making such as optimal timing of discontinuation and restarting as well 
as antithrombotic reversal, if feasible. 
In addition and separate to pure clinical knowledge and practice, the methodological quality 
of the available guidelines and recommendations becomes a critical component of evidence-based 
patient care in the era of evidence-based medicine. To the best of our knowledge, the available 
recommendations on the perioperative management of antithrombotic treatment in the urological 
setting has not been systematically reviewed and methodologically assessed.  
The current review will identify the clinical practice guidelines (CPGs) and clinical practice 
recommendations (CPRs) on the management of antiplatelets and anticoagulants in the acute and 
elective urological surgical setting, as provided by four main medical and surgical organizations. In 




A pragmatic search of the available electronic databases and guidelines websites, including 
PubMed, EMBASE and the National Guideline Clearinghouse (www.guideline.gov) was performed. 
Databases were searched from their inception date to March 2019; only English-written guidelines 
were searched and retrieved. Following identification of guidelines authors reached consensus on 
internationally endorsed CPGs or CPRs with direct clinical relevance to the urological surgical practice.  
CPGs/CPRs were reviewed and main recommendations were summarized into tables. Two 
independent trained appraisers (KD and MO) used the AGREE II (Appraisal of Guidelines for REsearch 
and Evaluation) instrument to evaluate the three CPGs. AGREE II is an international, validated 
instrument that assesses the methodological quality and integrity of the Guidelines and is globally 
endorsed by several health care organizations.[19] It consists of 23 separate items evaluating six 
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different domains: 1) scope and purpose (items 1–3); 2) stakeholder involvement (items 4–6); 3) rigor 
of development (items 7–14); 4) clarity of presentation (items 15–17); 5) applicability (items 18–21); 
and 6) editorial independence (items 22–23). The AGREE II instrument uses a 7-point scoring system 
for each one of these 23 individual items, with a score of 1 indicating no/poor information provided 
for the appraised item while a score of 7 indicates exceptional quality of reporting. There is also a final 
domain assessing the overall quality of the Guideline (score 1-7) and a separate item pertaining to 
whether the reviewer would recommend the appraised guideline for clinical use (Yes, Yes with 
modifications, No). 
Scores for each domain are calculated by summing up all appraisers’ scores of all individual 
domain items and by scaling the total as a percentage of the maximum possible score for that domain 
using the formula (Obtained score – Minimum possible score) x 100/(Maximum possible score – 
Minimum possible score). According to the AGREE II Consortium, there are no set scores used to 
differentiate between high- and poor-quality guidelines; instead, this decision should be made by the 




Four different internationally endorsed CPGs and CPRs were identified following the initial 
search. These included the CPGs of the European Association of Urology (EAU) published in 2018,[20, 
21] the American College of Chest Physicians (ACCP) CPG published in 2012[22] and the European 
Society of Cardiology/European Society of Anaesthesiology (ESC/ESA) CPGs published in 2014.[23] 
Finally, the CPRs provided by the International Consultation on Urological Disease (ICUD)/American 
Urologic Association (AUA) were included in this pragmatic review.[24]The overall results of the 
appraisal of the three CPGs with the use of the AGREE-II instrument are presented in Table 2.  
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The applicability of the AGREE II instrument to assess the ICUD/AUA publication was also 
assessed by the reviewers. The AUA/ICUD white paper reported consensus-based recommendations 
and as the authors reported in their publication, they focused on constructing a review based on a 
systematic literature search, instead of developing a full CPG. Thus, to ensure methodological 
consistency, it was decided that AGREE II would not be used to appraise the AUA/ICUD 
recommendations which should be regarded as CPRs instead of CPGs.  
With respect to overall guideline assessment, the EAU and ESC/ESA CPGs had scores of 83.3, 
and 75, respectively, while the ACCP CPGs scored lower (66.7) mainly because they were considered 
to require revision to ensure updated recommendations. As regards scope and purpose, the ACCP 
Guidelines had the highest score (88.9) compared to the EAU (63.9) and ESC/ESA (52.8) CPGs. The 
ESC/ESA Guidelines scored higher in terms of stakeholder involvement (55.6 versus 52.8 for both EAU 
and ACCP CPGs), and for applicability (70.8 versus 33.3 for ACCP and 8.3 for EAU). The EAU Guidelines 
had the highest score as regards rigor of development (56.3 versus 55.2 for ESC/ESA and 43.8 for ACCP 
Guidelines), clarity of presentation (94.4 compared to 83.3 for ACCP and 75.0 for ESC/ESA CPGs), while 
the EAU and ACCP CPGs scored 100 for editorial independence compared to 91.7 for those of the 
ESC/ESA. 
For all CPGs, modifications were deemed necessary to further improve the quality of their 
recommendations and methods.  Whereas a similar pattern of scoring was identified across almost all 
the examined CPG domains, discrepancies were identified in applicability, with a range of 62.5 points 
(8.3–70.8).  
Table 3 provides a detailed summary of the CPGs and CPRs relating to the perioperative 
management of antithrombotic agents. For brevity, all recommendations will be presented and 






With respect to the management of patients who are using antiplatelet agents, most CPGs/CPRs 
focused on aspirin and clopidogrel, although additional recommendations regarding the management 
of patients on ticagrelor or prasugrel also were provided. It is noteworthy that all CPGs/CPRs discuss 
the need for the clinician to weigh the risks of perioperative bleeding against the risk of 
thromboembolic complications.  
In general, the main clinical settings discussed in the CPGs/CPRs represent the perioperative 
management of monotherapy (with aspirin or other antiplatelets) and dual antiplatelet treatment 
(with aspirin and one P2Y12 inhibitor). While a variety of recommendations is noted in regards to the 
perioperative management of aspirin monotherapy (EAU advises stopping prior to operation based 
on recent evidence, AUA and ACCP recommend in general continuing with aspirin through the time of 
surgery and ESC/ESA advise individualized approach), it is clear that all CPGs/CPRs agree on stopping 
all remaining antiplatelets (such as clopidogrel or ticagrelor) preoperatively.  
The challenging management of DAPT in the elective/urgent/emergency surgical setting is 
highlighted across all four CPGs/CPRs. Deferring any elective procedures until the completion of the 
DAPT course is clearly the consensus recommendation with the clinicians advised to explore simpler 
and less invasive management alternatives for a minimum time period that depends on the original 
clinical indication for DAPT (e.g. insertion of bare metal or drug eluting stent). If this is not possible 
(for example in the case of a clinical emergency), then multidisciplinary approach is encouraged by all 
organizations and different recommendations are provided such as continuing with the DAPT 
perioperatively (EAU and ACCP), or continuing with single antiplatelet treatment with aspirin around 
the time of surgery with or without bridging based on indications and with a 24/7 catheterization 
laboratory available to treat patients in case of perioperative TEs (ESC/ESA). 
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AUA is the only association that provides with procedure-specific recommendations. Patients on 
low-dose aspirin can have prostatic biopsies while remaining on the antiplatelet drug with a risk of 
minor bleeding approximately a third higher than the controls. Laser operations such as ureteroscopy 
or laser prostatectomy can can be safely performed without stopping the AP agent.  For more 
complicated procedures such as PCNL, TURP, or even more invasive operations (e.g. radical 
prostatectomy or partial nephrectomy) this is not the case and therefore AP should be stopped and 
bridging should be offered prior to the procedure. For ESWL, AP drugs should be discontinued or 
reversed prior to the ESWL session, although no specific timings of cessation/reinstitution of 
antiplatelet drugs were provided, as they warrant multidisciplinary and case-specific discussions.  
Anticoagulant agents 
Two main categories of anticoagulants are discussed by the CPGs/CPRs discussed in this review: 
warfarin and the newer DOACs. It should be noted that the ACCP Guidelines do not address 
perioperative DOAC management. With respect to procedure-specific guidance, the 
recommendations provided by the AUA remain the same with the ones provided in the case of APs. 
In regards to perioperative management of warfarin, all four CPGs/CPRs use a risk stratification 
approach to provide with recommendations. For patients on warfarin at low risk for TEs, warfarin 
should be stopped 3-5 days prior to procedure; warfarin can be restarted after 1-4 days depending on 
the CPG/CPR. All CPGs/CPRs agree that patients at high risk for TEs will need to stop warfarin 5 days 
before the procedure and start bridging with LMWH 4 days before the operation or once INR <2.0. 
ACCP Guidelines encourage a patient/surgery-based approach in patients at moderate risk for TEs 
where the clinician can decide on whether bridging should or should not be offered. ESC/ESA CPGs 
and AUA CPRs tend to favour the use of UFH as bridging agent in patients with metallic heart valves, 
ACCP CPGs discuss both LMWH and UFH while EAU CPGs only recommend LMWH. 
For the management of DOACs, some variation in recommendations is noted reflecting the new 
practice and constantly evolving evidence. EAU CPGs follow the same approach with warfarin: stop 
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preoperatively with no bridging; if the TE is recent, defer operation if possible – if not, continue with 
the anticoagulants around the procedure or offer bridging.  AUA also advise consultation with 
cardiology/haematology for urgent/emergency procedures. While AUA approaches standard and high 
risk procedures in the same way (stop DOAC 2-5 days prior to operation, bridging might be required) 
ESC/ESA offer different recommendations based on the risk of bleeding (stop DOACs preoperatively 
for 2-3/4-5 times their biological half-lives for low and high risk procedures, respectively) and in 
general recommends against bridging except in case surgical intervention is delayed for several days.  
Of note, ACCP Guidelines do not provide with recommendations on the management of DOACs as 
their use was not common when ACCP CPGs were released. Recently however, Douketis et al. 
published the results of the PAUSE (Perioperative Anticoagulation Use for Surgery Evaluation) study, 
assessing a simple proposed discontinuation/resumption strategy for patients with AF on DOACs who 
were to be offered various types of elective surgery (not urological, necessarily).[25] DOACs were 
stopped 1 or 2 days before a low- or high-risk procedure respectively, and were resumed 1 day after 
a low risk procedure or 2-3 days after a high-risk one. In more than 3000 patients included, the rates 
of major bleeding and arterial thromboembolism were low, regardless of the DOAC agent. 
Methodological aspects 
With respect to the methodological quality of the CPGs assessed in this review, some critical points 
need to be discussed and clarified. First, the methodological framework of the CPGs discussed in this 
review is not the same and therefore, the processes linking the available evidence to the provided 
recommendations can vary significantly. In addition, the levels of evidence and strengths of 
recommendations as presented in the CPGs might not be exactly the same as the Guidelines 
organisations can be using different grading systems and therefore, interpreting the statements and 




Although AGREE II is a validated instrument that assesses the methodological quality of health system 
guidelines, there are no pre-defined thresholds to define high, moderate and low quality guidelines 
due to the lack of empirical basis to define them. An arbitrary threshold of <30% to define low quality 
and >70% to define high quality can be used for the subdomains as users should be encouraged to 
avoid using the overall score as the sole indicator of methodological quality. Moreover, depending on 
the primary research aim solitary domains could have a higher weight (e.g. stakeholder involvement 
and applicability) and therefore their scores will require different interpretation. Thus, we discourage 
the readers from preferring a specific guideline over another one based on the AGREE II results only.  
The 3 CPGs assessed in the current SR had high scores in Editorial Independence (best domain for all 
3) and Clarity of Presentation and moderate scores in Stakeholder Development and Rigor of 
Development. In Scope and Purpose, EAU and ESC/ESA CPGs had moderate scores while ACCP CPGs 
scored fairly high. The most impressive score range was detected in Applicability, with EAU CPGs 
scoring very low, ACCP CPGs having low score and ESC/ESA scoring rather moderate-to-high.  
It is clear that the CPGs panel need to work more on identifying the facilitators and barriers to their 
Guidelines application and on how their recommendations can be applied. In addition, auditing 
criteria and processes need to be clearly provided to further improve the Applicability domain score. 
With respect to the Rigour of Development domain, main weak points were clear descriptions of the 
methodology and in specific the link between recommendations and supporting evidence, the 
external review and the update procedures. In Stakeholder Development, clear description of the 
target users of the CPGs was not frequently provided and it was unclear how the views and 
preferences of patients were sought and taken into consideration.  The lack of clear descriptions of 
the health questions, objectives and target population covered in the CPGs can explain the rather 
moderate scores in Scope and Purpose. For all 3 CPGs, reviewers felt that additional modifications 
were necessary to further improve the quality of recommendations and methods.  
Limitations and Strengths 
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A possible limitation of this review is the fact that only 4 CPGs/CPRs were included, presented, 
assessed and discussed. Indeed, a more inclusive approach could have been followed in this review 
with a more exhaustive literature search to give the reader a more holistic overview of the available 
literature and mainly the evidence-derived recommendations. There is a big number of international, 
national and departmental guidelines available currently but the aim of this review was to discuss the 
perioperative management of the antithrombotic agents in the urological setting in specific. As a 
result, it was decided that the recommendations provided by the two main international urological 
associations (EAU and AUA) should be discussed. The ESC/ESA and ACCP CPGs do not exclusively refer 
to urological operations but provide with evidence based recommendations on the general 
perioperative management of antithrombotic medications and are endorsed by multiple medical and 
surgical societies globally. In addition, their clinical recommendations represent the main basis for 
guidelines provided by other associations. 
To the best of our knowledge, this is the first pragmatic review to summarise the evidence on the 
perioperative management of antiplatelet/anticoagulant agents in the urological setting with a critical 
assessment of the included CPGs. We feel that from a clinical perspective this will represent a helpful 
tool, will facilitate the decision-making process, simplify clinical practice and improve patient care. 
From the methodological view, the current review review will also highlight to the reader the 
methodological limitations, challenges and strengths behind the available evidence-based 
recommendations.  
Conclusions 
The perioperative management of antithrombotic therapy in urological patients is potentially 
challenging but inconsistent CPG of varying quality may create uncertainty as to best practices to 
minimize thromboembolic and bleeding risk. Various recommendations have been provided by 
several surgical and medical organisations on the perioperative management of antiplatelet and 
antithrombotic agents in the urological field and are presented in the current review. Clinicians are 
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encouraged to critically endorse them to develop patient-specific evidence-based management plans 
tailored to meet individual needs. On the other hand, this review also reveals weaknesses and gaps in 
the quality of the available guidelines, highlighting the need for further improvement to the guidelines 
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